Sweden · Delayed Price · Currency is SEK AddLife AB Earnings Call Transcripts
Fiscal Year 2026
-
Q3 revenue rose 7% and adjusted EBITDA increased 11%, with margin expansion and stronger operating cash flow. Unicam and LEHNEN acquisitions added to growth; high acquisition activity is expected to continue amid regional differences and ongoing Spanish labor disruption.
-
Margins and profitability improved across all segments, with EBITA margin rising to 12.6% and strong growth in Labtech, Medtech, and Home Care. Recent acquisitions and advanced products drove earnings, while cash flow and leverage remain robust.
-
High margins sustained with EBITDA at 12.5% and strong growth in advanced products. Labtech and Medtech segments delivered robust performance, supported by recent margin-accretive acquisitions and improved European research funding.
Fiscal Year 2025
-
Q4 and full-year 2025 delivered strong profit and margin improvements, with robust cash flow and reduced net debt. Both Labtech and Medtech segments expanded margins, while acquisitions and portfolio optimization supported future growth.
-
Strong organic and acquired growth drove significant margin and profit improvements, with leverage reduced below target and robust cash flow. Platform acquisitions in Europe boosted segment performance, and a focus on advanced products strengthened margins.
-
Margin and profit improvements drove EBITA above 12% in both segments, with 5% revenue growth and strong cash flow. Acquisition of Edge Medical and a robust M&A pipeline position the group for further growth.
-
EBITDA margins improved significantly in both Labtech and Medtech, with strong cash flow and reduced leverage enabling renewed acquisition activity. Revenue grew 5% overall, and portfolio optimization plus efficiency initiatives drove margin gains.
Fiscal Year 2024
-
Strong sales and EBITDA growth in 2024, with significant margin and cash flow improvements driven by efficiency initiatives and portfolio optimization. Both Labtech and Medtech segments delivered robust results, and the outlook for 2025 is positive with increased acquisition activity planned.
-
Q3 delivered 3% organic growth and stable margins despite seasonal slowness and delayed investments. Medtech margins improved, Labtech faced temporary margin pressure, and the Bonsai Lab acquisition strengthened the portfolio. Cost savings from Camanio closure and strong cash flow support a positive Q4 outlook.
-
Strong organic growth in both Medtech and Labtech drove a 21% EBITDA increase and improved margins, supported by restructuring and efficiency gains. Cash flow and debt metrics strengthened, while the acquisition of Bonsai Lab is set to boost future profitability.